A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
Supplementary Data
Supplementary Data
Files in this Data Supplement:
Supplementary Data
- Docx file
Supplementary Tables1-4
- docx file